Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select in China

Genetics Investing

Oxford Immunotec Global (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Selectkit by the China Food and Drug Administration (CFDA). As quoted in the press release: The T-Cell Select kit was designed as an immune cell separation reagent kit to simplify workflow, improve throughput, and reduce hands-on time and labor …

Oxford Immunotec Global (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Selectkit by the China Food and Drug Administration (CFDA).

As quoted in the press release:

The T-Cell Select kit was designed as an immune cell separation reagent kit to simplify workflow, improve throughput, and reduce hands-on time and labor costs in performing the T-SPOT®.TB test. With the T-Cell Select kit, blood samples collected in a single standard blood tube can be stored for up to 54 hours at room temperature before use, further extending the company’s unrivaled simplicity and logistics advantages for customers.

Click here to read the full press release.

The Conversation (0)
Ă—